StocksMediumUpdated•Originally published 4 November 2026•Updated 5 November 2026•
1 min read
Schrödinger Raises 2026 Guidance Following Q3 Earnings Beat
Key Facts
1Schrödinger reported a GAAP EPS loss of $0.50, beating analyst estimates by $0.17.
2Company revenue reached $64.49M, surpassing expectations by $16.86M.
Schrödinger reported a GAAP EPS loss of $0.50 for the third quarter of 2026, beating analyst estimates by $0.17. Seeking Alpha reported that the company's revenue reached $64.49 million, surpassing expectations by $16.86 million.
The company raised its 2026 drug discovery revenue guidance to a range of $75 million to $85 million and outlined an Annual Contract Value (ACV) target of $222 million to $232 million. SDGR was trading at $27.18 on November 3, 2026, supported by software revenue of $38.2 million.